IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke

Stroke

Volumn 43, Issue 10, 2012, Pages 2659-2665

  Fernández Cadenas, Israel ^a   Del Río Espínola, Alberto ^a   Giralt, Dolors ^a   Domingues Montanari, Sophie ^a   Quiroga, Adoracion ^a   Mendióroz, Maite ^a   Ruíz, Agustin ^b,c   Ribó, Marc ^a   Serena, Joaquin ^d   Obach, Victor ^e   Freijo, Mari Mar ^f   Martí Fábregas, Joan ^g   Delgado, Pilar ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Vall d'Hebrón Hospital ^*  (Spain)

^c Institut Catala de Neurociencies Aplicades   (Spain)

^d GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL DE BASURTO   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

genetics; pharmacogenetics; recanalization; stroke; tPA

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DNA ISOLATION; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FIBRINOLYSIS; FUNCTIONAL ASSESSMENT; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANKIN SCALE; RECANALIZATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; COHORT STUDIES; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; INTERLEUKIN-1BETA; LOGISTIC MODELS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SPAIN; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84866720680     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.657007     Document Type: Article

References (15)

1. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, et al. Thrombolysis in Brain Ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke. 2001;32: 89-93. (Pubitemid 32063829)
2. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369:275-282. (Pubitemid 46138121)
3. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000;31:1812-1816. (Pubitemid 30620455)
4. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, et al. Influence of thrombin-activable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost. 2007;5:1862-1868. (Pubitemid 47288943)
5. Fernandez-Cadenas I, Mendioroz M, Munuera J, Alvarez-Sabin J, Rovira A, Quiroga A, et al. Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with tPA. Thromb Haemost. 2009;102:759-764.
6. Iacoviello L, Di Castelnuovo A, Gattone M, Pezzini A, Assanelli D, Lorenzet R, et al. IGIGI Investigators. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol. 2005;25:222-227. (Pubitemid 40054280)
7. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet. 2006;15: 519-529. (Pubitemid 43205418)
8. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340-3346.
9. Mazzotta G, Sarchielli P, Caso V, Paciaroni M, Floridi A, Floridi A, et al. Different cytokine levels in thrombolysis patients as predictors for clinical outcome. Eur J Neurol. 2004;11:377-381. (Pubitemid 39272941)
10. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 2004;50:1976-1983. (Pubitemid 38725110)
11. Domingues-Montanari S, Fernández-Cadenas I, Del Río-Espinola A, Mendioroz M, Fernandez-Morales J, Corbeto N, et al. KCNK17 genetic variants in ischemic stroke. Atherosclerosis. 2010;208:203-209.
12. Kiefer TL, Becker RC. Inhibitors of platelet adhesion. Circulation. 2009; 120:2488-2495.
13. Lacquemant C, Gaucher C, Delorme C, Chatellier G, Gallois Y, Rodier M, et al. Association between high von Willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group. Kidney Int. 2000;57:1437-1443. (Pubitemid 30207903)
14. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, et al; from The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) group. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor. Circulation. 2010;121:1382-1392.
15. Gissel M, Undas A, Slowik A, Mann KG, Brummel-Ziedins KE. Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. Thromb Res. 2010;126:262-269.